Research Compliance Activity and Turn-Around-Time (TAT) Summary Report Fiscal Year 2016-2017 (7/1/2016 to 6/30/2017)

TAT calculated from submission date to date of approval. TAT not calculated for continuing reviews.

Institutional Biosafety Committee (IBC) - Bloomington										
	Q1 TAT		Q2 TAT		Q3 TAT		Q4 TAT		FY-END TAT	
	Mean	Median	Mean	Median	Mean	Median	Mean	Median	Mean	Median
Full Board								Full Board		
New Studies - Full Board (to review)	20.0	21.5	34.3	22.5	18.7	16.0	31.5	33.0	26.1	23.3
New Studies - Full Board (to approval)	42.8	42.0	49.3	36.0	38.5	29.0	58.5	63.0	47.3	42.5
Exempt									Exempt	
New Studies - Exempt (to determination)	17.6	15.0	30.0	28.50	31.75	29.5	58.0	58.0	34.3	32.8
Amendments									Amendments	
Amendments - Minor	6.9	1.0	5.1	3.5	6.9	2.0	3.9	1.0	5.7	1.9
Amendments - Major	n/a	n/a	18.8	16.5	39.0	56.0	48.3	51.0	35.3	41.2

^{*}Note: TAT includes a "pre-review" time frame occurring prior to full committee meeting.

	Q1 (Jul-Sep)			Q2 (Oct-Dec)			Q3 (Jan-Mar)			Q4 (Apr-Jun)		
			Throughput/			Throughput/			Throughput/			Throughput/
Area Activities/Throughput (T)	Received	Completed	% Backlogged									
New Studies - Full Board	4	4	0	4	4	0	5	4	-1 (20.0%)	4	4	0
New Studies - Exempt	6	3	-3 (50.0%)	4	6	2	5	4	-1 (20.0%)	2	2	0
Amendments - Minor	38	29	-9 (23.7%)	20	22	2	64	64	0	34	38	4
Amendments - Major	2	0	-2 (100.0%)	5	4	-1 (20.0%)	4	5	1	6	7	1
Continuing Reviews	17	17	0	8	11	3	21	21	0	9	6	-3 (33.3%)
TOTAL	67	53	-14 (20.9%)	41	47	6 (-14.6%)	99	98	-1 (1.0%)	55	57	2 (-3.6%)

	Q1	Q2	Q3	Q4	FY
Area Training Activities	(Jul-Sep)	(Oct-Dec)	(Jan-Mar)	(Apr-Jun)	TOTALS
Presentations (# of events)	0	0	0	0	0

Reportable Events/Activities	Q1 (Jul-Sep)	Q2 (Oct-Dec)	Q3 (Jan-Mar)	Q4 (Apr-Jun)	FY TOTALS
Immediate OBA Report	0	0	0	0	0
30 Day OBA Report	0	0	2	0	2
Lab Accident/Injury/Exposure	0	0	0	0	0

Reporting Agency: NIH Office of Biotechnology Activites (OBA)